YG1699

DRUG4 trials

Sponsors

Youngene Therapeutics Inc., Ltd., RenJi Hospital

Conditions

Diabete MellitusDiabetesDiabetes MellitusDiabetes Mellitus, Type 1HemodialysisRenal Insufficiency, ChronicType1diabetes

Phase 1

A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699

CompletedNCT03953092

Youngene Therapeutics Inc., Ltd.Diabete Mellitus

Start: 2019-05-01End: 2019-11-13Updated: 2021-01-11

To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699（Antidiabetic） in Healthy Chinese Sbjects

CompletedNCT05089617

Youngene Therapeutics Inc., Ltd.Diabetes Mellitus

Start: 2022-01-09End: 2022-08-12Updated: 2023-01-31

PK and PD of YG1699 in CKD Patients With Diabetes

Not yet recruitingNCT06648876

RenJi HospitalDiabetes, Hemodialysis, Renal Insufficiency, Chronic

Start: 2024-10-31End: 2025-10-30Target: 20Updated: 2024-10-18

Phase 2

A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes

CompletedNCT04956263

Youngene Therapeutics Inc., Ltd.Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1 +1

Start: 2021-06-17End: 2022-07-19Updated: 2022-07-28

Related Papers

138-LB: First-in-Human Study of YG1699, an SGLT1 and SGLT2 Dual Transporter Inhibitor

Diabetes2020-06-011 citations